[News] Osimertinib improves progression-free survival in NSCLC

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), increases progression-free survival in patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC) compared with other EGFR TKIs, according to the results of a new study.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: News Source Type: research